Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

Interim analysis shows misetionamide is very well tolerated in combination with gemcitabine; rates of confirmed response, stable disease, and progression-free survival compare favorably with ...

Big news! ASCO lands a major nine-figure contract with a North Sea operator. This game-changer highlights our 60 years of ...

Compared with chemotherapy alone, neoadjuvant nivolumab plus chemotherapy extends overall survival in patients with resectable non-small cell lung cancer.

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an ...

The oncology community has sounded the alarm over the Trump administration's 2026 budget proposal, which includes near-40% ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...